The latest data point for CVS's EPS in Q4'25 stands at 2.33 USD, marking a significant recovery from the sharp decline in the prior quarter and representing the highest value in the observed period from Q1'23 to Q4'25. Over the 12-quarter timeframe, CVS's EPS exhibited high volatility with an overall fluctuating trend, starting at 1.66 USD in Q1'23 and peaking at 2.33 USD in Q4'25, but featuring notable declines such as a drop to 0.07 USD in Q3'24 and a plunge to -3.13 USD in Q3'25 amid operational challenges. Year-over-year EPS growth was predominantly negative, with severe contractions like -96% in Q3'24 and an extreme -4,571% in Q3'25, though sporadic rebounds occurred, including +168% in Q3'23 and +78% in Q4'25, underscoring inconsistent profitability driven by sector-specific pressures in healthcare retail.